Amarin reported $18.97M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.84B 205M Sep/2026
Alnylam Pharmaceuticals USD 342M 5.92M Sep/2026
Amarin USD 18.97M 1.03M Dec/2025
AstraZeneca USD 4.07B 1.73B Sep/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
DBV Technologies USD 15.8M 2.4M Sep/2026
GlaxoSmithKline GBP 2.16B 39M Sep/2026
Halozyme Therapeutics USD 58.24M 1.24M Sep/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 366.3M 16.8M Sep/2026
Novartis USD 3.08B 163M Sep/2026